The fight against cancer enters a transformative era with the launch of the BRECISE project, an innovative five-year initiative co-funded by the Innovative Health Initiative (IHI) and the private sector under the Horizon Europe program. The official launch took place in Madrid on March 20-21, 2025. BRECISE aims to revolutionize personalized oncology for prostate and bladder cancer by integrating Next-Generation Sequencing (NGS), Artificial Intelligence (AI), and ex vivo drug testing to develop advanced biomarkers.
Main targets of BRECISE:
- Clinical Validation of Biomarkers: Multicenter studies for the validation of biomarkers for risk stratification, treatment response, and disease progression.
- Precision Medicine with Artificial Intelligence: Development of artificial intelligence models to enhance diagnostic accuracy and predict treatment outcomes.
- Ex Vivo Tumor Testing: Use of microtumor and organoid models to evaluate drug response prior to treatment.
- Regulatory Alignment: Ensuring compliance with European health regulatory frameworks for the faster adoption of biomarkers in healthcare.
Why this is important:
-For Patients: More accurate diagnoses, personalized treatments, and early detection of treatment resistance.
-For Healthcare Systems: Optimization of therapeutic strategies, cost reduction, and standardization of biomarker validation.
-For Policymakers and Industry: Strengthening European leadership in personalized oncology and promoting public-private partnerships.
Under the leadership of Philips and South East Technological University (SETU), BRECISE brings together 12 private, 15 public, and 3 affiliated partners, including universities, research centers, healthcare providers, and patient organizations. This multi-stakeholder approach ensures that scientific discoveries are translated into clinical impact in the real world.
